In brief
- A phase 1 trial with 56 healthy adults tested single doses of psilocybin between 0.5 and 4 mg against a placebo.
- Subjective effects were distinguishable from placebo starting at 2.5 mg, with no dose-dependent impairment in attention, working memory, or impulse control (aside from minor, transient signals at 2 hours), and minimal alterations in consciousness.
- This is a small study on healthy volunteers funded by the product’s developer; it does not yet provide evidence of clinical efficacy.
Most psilocybin trials utilize doses ranging from 10 to 25 mg, which necessitate a supervised session lasting several hours. A team based in Canada and the United States has now published a randomized, double-blind, placebo-controlled trial in the journal Pharmaceuticals that explores the opposite end of the spectrum: very low doses, seeking the point at which effects begin to manifest.
How it was conducted
The study involved 56 healthy adults, half male and half female, with an average age of 37.5 years. Participants were organized into seven sequential cohorts of eight people, with a three-to-one ratio of psilocybin to placebo. Oral doses were 0.5, 1.0, 1.5, 2.5, 3.5, and 4.0 mg, with the 4.0 mg dose repeated in two cohorts. Between cohorts, a safety committee reviewed the data before authorizing the next step. Volunteers remained monitored for 24 hours and were followed up after seven days.
An interesting design detail: to reduce expectation bias, participants were told during the consent process that they might receive one of five different substances. The authors believe this masking was particularly effective at the lowest doses.
What was measured and what appeared
Psilocin, the active metabolite, appeared in the blood within 15 to 30 minutes and peaked around one hour. Its half-life was short: approximately 1.6 hours with 0.5 mg and 2.3 to 2.5 hours with the other doses. The mean peak was 835 pg/ml with 0.5 mg and 5,127 pg/ml with 4.0 mg.
Regarding subjective experience, “drug effect” scores surpassed the placebo starting at 2.5 mg, with the clearest responses at 3.5 and 4.0 mg, though with significant individual variability. The sensation of “being high” increased sharply at those two doses but was short-lived. The five dimensions of the altered states of consciousness questionnaire remained below 40%, and the most prominent—reduced vigilance—was interpreted as mild drowsiness. Hallucination scores did not increase with the dose; the highest mean was actually recorded by the placebo group.
Pupil size did respond in a dose-dependent manner, an objective indication that the substance was active. Tests for sustained attention, working memory, and reaction times remained at baseline; there were minor signals at two hours, such as slightly slower reaction times, which recovered by the four-hour mark.
There were no serious adverse effects or dropouts. All events were mild, the most frequent being drowsiness, which also occurred in the placebo group (5 out of 14 people). Three participants reported feeling “high,” only at 3.5 and 4.0 mg, and one participant at 4.0 mg noted an auditory alteration that, upon review, was described as transient disorganized thinking.
What it implies
The study provides something that was previously missing: controlled data on a dose range that many people use naturalistically without pharmacological information. According to the study, there is a window between 2.5 and 3.5 mg with measurable action but no marked perceptual alteration, and the authors propose 3 mg as a candidate dose for subsequent trials on generalized anxiety.
The authors themselves note the limitations: cohorts of six people, descriptive rather than inferential analysis, healthy volunteers with a limited range of baseline anxiety (mild to moderate), and cognitive tests that did not coincide with the one-hour peak. The study was retrospectively registered on ClinicalTrials.gov in July 2026 and was funded by Diamond Therapeutics, whose staff co-authored the article and participated in the safety committee and dose-escalation decisions. That an effect is measurable does not prove it is useful, and no clinical benefit was measured here. Those interested in microdosing will find context for these still-scarce data in our microdosing dossier and in our analysis of the largest microdosing meta-analysis.
Source
- Levy-Cooperman N, Sellers E, Glue P et al. Pharmaceuticals. A Randomized, Double-Blind, Placebo-Controlled Single-Ascending-Dose Study to Identify a Subperceptual Dose of Psilocybin in Healthy Adults. Pharmaceuticals (Basel) 19(9), September 21, 2026.
Educational content written from a harm reduction perspective and with respect for individual freedom. It is not a substitute for advice from a healthcare professional and is not intended to encourage or condemn any drug use.
